Disease Overview
Why Psoriasis Demands Specialized BRA
The psoriasis treatment landscape is among the most competitive in immunology, with multiple mechanism classes achieving PASI 90/100 responses. Differentiating therapies increasingly depends on long-term safety profiles and benefit-risk positioning for HTA bodies.
IL-17 Inhibitor Safety Profiling
IL-17A/F inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab) carry specific risks including Candida infections, inflammatory bowel disease exacerbation, and suicidal ideation signals (brodalumab REMS). Comparative safety profiling across this class is essential for positioning and formulary decisions.
Competitive Class Comparison
With IL-23 inhibitors showing superior long-term remission rates and favorable safety profiles, comparative BRA between IL-17, IL-23, TNF, and TYK2 inhibitors is critical for treatment guidelines, formulary negotiations, and label differentiation. Head-to-head trial data (IMMerge, ECLIPSA) requires integrated interpretation.
Long-Term Safety in Chronic Use
Psoriasis patients receive biologics for decades. Long-term safety data extending beyond 5-year clinical trial windows is critical for infection risk (tuberculosis, opportunistic infections), malignancy surveillance, and cardiovascular outcomes. Registry data integration (PSOLAR, BioCAPTURE, PsoBEST) is essential.
Platform Capabilities
How ArcaScience Addresses Psoriasis BRA
Our platform is configured with comprehensive psoriasis and PsA data, comparative biologic safety models, and HTA-aligned output templates for value-based access negotiations.
Psoriasis Data Coverage
1,900+ psoriasis/PsA clinical trials including VOYAGE, ECLIPSE, IMMerge, KEEPsAKE, SPIRIT, and BE VIVID datasets. Long-term registry data from PSOLAR (12,000+ patients), BioCAPTURE, and PsoBEST. Real-world evidence covering biologic switching patterns and long-term outcomes.
Explore Data Engine →Comparative Biologic AI Models
AI models for cross-class safety comparison (IL-17 vs. IL-23 vs. TNF vs. TYK2), Candida infection signal detection, IBD exacerbation risk in IL-17-treated patients, cardiovascular safety monitoring in psoriasis populations (elevated baseline CV risk), and immunogenicity-driven efficacy loss prediction across biologics.
Explore AI Models →Dermatology Regulatory Outputs
PSURs with comparative class-level safety analysis, RMPs with infection monitoring and IBD screening protocols, competitive BRA positioning reports for market access, and HEOR dossiers with DLQI/PASI-based utility analyses for NICE, G-BA, HAS, and PBAC submissions.
Explore Outputs →Psoriasis Intelligence
Platform Performance in Psoriasis
Psoriasis-related adverse event data points
Faster comparative safety profiling
Mechanism classes compared
Psoriasis submissions supported
Case Evidence — Psoriasis
Sanofi Dermatology BRA Acceleration
Challenge
Sanofi needed to accelerate the benefit-risk assessment for their IL-13 inhibitor (dupilumab) label extension into moderate-to-severe psoriasis, requiring comparative safety positioning against established IL-17 and IL-23 inhibitors for regulatory and HTA submissions across 8 markets simultaneously.
Result
ArcaScience delivered comprehensive comparative BRA across 5 mechanism classes in 8 weeks, supporting simultaneous submissions with market-specific safety positioning that highlighted dupilumab's favorable infection profile versus IL-17 inhibitors.
Faster BRA delivery
Markets submitted simultaneously
Director, Dermatology Safety
Sanofi
Frequently Asked Questions